New tools for improving detection and treatment of Plasmodium vivax (P. vivax) malaria, like single-dose tafenoquine and point-of-care diagnostics, are expanding access to radical cure treatment options—but turning innovation into impact requires more than approval. This session brings together country experiences and global insights on the policies, tools, and operational systems needed to ensure people can reach the care they need. We’ll explore the practical steps that scale approval of new innovations into real-world access and the progress being made in the fight against P. vivax malaria.
What you’ll learn:
- How Brazil moved from regulatory approval to nationwide introduction of tafenoquine, including lessons from feasibility studies to scale-up.
- The critical role of diagnostics in the safe, effective rollout of radical cure treatment.
- The latest evidence on tafenoquine use.
- How to align emerging evidence with WHO guidelines.
Please note that simultaneous Portuguese interpretation will be available.
SPEAKERS:
Dr. Gonzalo Domingo, Global Program Director, Diagnostics, PATH
Dr. Marcus Lacerda, MD, PhD, Public Health Specialist at Fiocruz Amazônia and Medical Researcher at the Fundação de Medicina Tropical Doutor Heitor Vieira Dourado
Prof. Kamala Thriemer, Senior Principal Research Fellow, Menzies School of Health Research, Darwin, Australia
Dr. Peter Olumese, Technical Lead, Malaria Case Management, Malaria and Neglected Tropical Diseases Department, World Health Organization, Geneva
Dr. Neena Valecha, MBBS, MD, FAMS, FNASc; Senior Technical Adviser, Medicines for Malaria Venture; Consultant, Gates Foundation; Chair, Indian Council of Medical Research; Member, Regional Technical Advisory Group, WHO SEARO; Adjunct Faculty, Public Health Foundation India
Join the conversation
View all past and upcoming PATH Live Forums
PATH Live Forums are curated live conversations with experts from PATH and our partners, with plenty of time for your questions.